美满环素对大鼠肺炎模型中 的药效学研究。
Pharmacodynamics of Minocycline against in a Rat Pneumonia Model.
机构信息
The Medicines Company, San Diego, California, USA.
The Medicines Company, San Diego, California, USA
出版信息
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01671-18. Print 2019 Feb.
Abstract
Minocycline is currently approved in the United States for the treatment of infections caused by susceptible isolates of spp. The objective of these studies was to determine the minocycline exposures associated with an antibacterial effect against in a rat pneumonia model. Rats received minocycline doses as 30-min intravenous infusions. In the rat pneumonia model, six clinical isolates of with MICs ranging from 0.03 to 4 mg/liter were studied. In this model, minocycline produced a bacteriostatic effect with a free 24-h area under the concentration-time curve (AUC)/MIC ratio of 10 to 16 and produced 1 log of bacterial killing with a free 24-h AUC/MIC of 13 to 24. These exposures can be achieved with the current FDA-approved dosage regimens of intravenous minocycline.
摘要
米诺环素目前已获美国批准，用于治疗 spp 敏感分离株引起的感染。这些研究的目的是确定米诺环素暴露量与肺炎大鼠模型中 的抗菌作用相关。大鼠接受米诺环素剂量为 30 分钟静脉输注。在肺炎大鼠模型中，研究了 6 株临床分离株，其 MIC 范围为 0.03 至 4mg/L。在该模型中，米诺环素产生抑菌作用，游离 24 小时浓度-时间曲线下面积（AUC）/MIC 比值为 10 至 16，游离 24 小时 AUC/MIC 为 13 至 24，可产生 1 对数的细菌杀灭作用。这些暴露量可通过目前 FDA 批准的静脉用米诺环素剂量方案实现。
相似文献
1
Pharmacodynamics of Minocycline against in a Rat Pneumonia Model.
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01671-18. Print 2019 Feb.
2
Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02371-16. Print 2017 May.
3
Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.
Antimicrob Agents Chemother. 2015 May;59(5):2720-5. doi: 10.1128/AAC.04110-14. Epub 2015 Feb 23.
4
Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.
Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.
5
Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
J Antimicrob Chemother. 2009 May;63(5):982-7. doi: 10.1093/jac/dkp056. Epub 2009 Mar 11.
6
In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.
7
Pharmacodynamics of Meropenem against Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02388-19.
8
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4047-54. doi: 10.1128/AAC.02994-15. Print 2016 Jul.
9
Enhanced anti-biofilm activity of the minocycline-and-gallium-nitrate using niosome wrapping against Acinetobacter baumannii in C57/BL6 mouse pneumonia model.
Int Immunopharmacol. 2023 Feb;115:109551. doi: 10.1016/j.intimp.2022.109551. Epub 2023 Jan 6.
10
In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2007 May;51(5):1621-6. doi: 10.1128/AAC.01099-06. Epub 2007 Feb 16.
引用本文的文献
1
Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.
J Antimicrob Chemother. 2025 May 2;80(5):1420-1426. doi: 10.1093/jac/dkaf090.
2
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.
Clin Infect Dis. 2024 Jun 14;78(6):1451-1457. doi: 10.1093/cid/ciae093.
3
Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.
Clin Infect Dis. 2023 May 1;76(Suppl 2):S179-S193. doi: 10.1093/cid/ciad094.
4
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0145222. doi: 10.1128/aac.01452-22. Epub 2023 Mar 22.
5
Assessing Clinical Potential of Old Antibiotics against Severe Infections by Multi-Drug-Resistant Gram-Negative Bacteria Using In Silico Modelling.
Pharmaceuticals (Basel). 2022 Nov 30;15(12):1501. doi: 10.3390/ph15121501.
6
Metformin reverse minocycline to inhibit minocycline-resistant Acinetobacter baumannii by destroy the outer membrane and enhance membrane potential in vitro.
BMC Microbiol. 2022 Sep 12;22(1):215. doi: 10.1186/s12866-022-02629-4.
7
Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) .
Microorganisms. 2021 Oct 6;9(10):2104. doi: 10.3390/microorganisms9102104.
8
Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01809-20.
9
Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.
Infect Dis Ther. 2017 Jun;6(2):199-211. doi: 10.1007/s40121-017-0153-2. Epub 2017 Mar 29.
10
Intravenous Minocycline: A Review in Acinetobacter Infections.
Drugs. 2016 Oct;76(15):1467-1476. doi: 10.1007/s40265-016-0636-6.
本文引用的文献
1
Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.
Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.
2
Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.
Infect Dis Ther. 2017 Jun;6(2):199-211. doi: 10.1007/s40121-017-0153-2. Epub 2017 Mar 29.
3
Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
Ann Clin Microbiol Antimicrob. 2015 May 10;14:27. doi: 10.1186/s12941-015-0085-1.
4
Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center.
Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S388-93. doi: 10.1093/cid/ciu594.
5
A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.
Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S374-80. doi: 10.1093/cid/ciu613.
6
Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.
Clin Infect Dis. 2014 Dec 1;59 Suppl 6:S367-73. doi: 10.1093/cid/ciu706.
7
Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).
Diagn Microbiol Infect Dis. 2010 Nov;68(3):307-11. doi: 10.1016/j.diagmicrobio.2010.07.003.
8
Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
Int J Antimicrob Agents. 2009 Nov;34(5):395-401. doi: 10.1016/j.ijantimicag.2009.06.021. Epub 2009 Aug 8.
9
Current control and treatment of multidrug-resistant Acinetobacter baumannii infections.
Lancet Infect Dis. 2008 Dec;8(12):751-62. doi: 10.1016/S1473-3099(08)70279-2.
10
Acinetobacter baumannii: emergence of a successful pathogen.
Clin Microbiol Rev. 2008 Jul;21(3):538-82. doi: 10.1128/CMR.00058-07.
Zotero 插件